title: Variations of lipid profile in animals caused by adenosine analogs: N6 (amido-3-propyl) adenosine hydrochloride and (carboxamido-3-propylamino)-6-(triproprionyl) 2',3',5'beta (D-ribosyl)-9-purine.
abstract: N6-substituted adenosine analogues are powerful inhibitors of lipolysis in the adipose tissues of animals and humans, because of their agonist effect on A1 purine receptors. Using a model of hypertriglyceridemia provoked by intravenous injection of Triton WR 1339, we observed that Agr 529 [N6(amido-3-propyl)adenosine hydrochloride] at 2 mg.kg-1 intravenous in rabbits, and intraperitoneally and orally in rats led to a return of the levels of circulating triglycerides to normal values. In addition, Agr 529 and its prodrug, Agr 540 [(carboxamido-3-propylamino)-6-(triproprionyl)2', 3',5'beta(D-ribosyl)-9-purine] administered to rats at 3 and 30 mg.kg-1, respectively, returned plasma triglyceride concentrations to normal levels. Intravenous administration of Agr 529 to normal rats led to decreased concentrations of plasma fatty acids, phospholipids, triglycerides and total cholesterol as a function of dose. The decrease began at 0.1 mg.kg-1 and was highly significant at 3 mg.kg-1. In the same conditions, the intraperitoneal administration of Agr 529 caused a dose-dependent hypolipemia. There was no apparent effect on cholesterol and on the triglycerides of high density lipoproteins. A kinetic study showed that the antilipemic effect of Agr 529 intravenously injected at 3 mg.kg-1 began 30 minutes after the injection with a maximum effect at 2 hours. The effect persisted up to 8 hours after injection. The present results show that the administration of Agr 529 and Agr 540 to normal animals causes hypolipemia (decrease in fatty acids, phospholipids, triglycerides and cholesterol) and restores induced hypertriglyceridemia. These effects may be attributed to an interaction of the molecules with A1 purinergic receptors of adipose tissue.
authors.affiliation: Laboratoire d'Eutonologie Hôpital Boucicaut, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Laborit
authors.forename: H
authors.initials: H
authors.lastname: Hasni
authors.forename: C
authors.initials: C
authors.lastname: Baron
authors.forename: G
authors.initials: G
authors.lastname: Pierrefiche
authors.forename: H
authors.initials: H
authors.lastname: Laborit
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D002784:Cholesterol / Q000097:blood; D004195:Disease Models, Animal; D005227:Fatty Acids / Q000097:blood; D015228:Hypertriglyceridemia / Q000139:chemically induced / Q000188:drug therapy; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D010743:Phospholipids / Q000097:blood; D011355:Prodrugs / Q000494:pharmacology*; D011684:Purine Nucleosides / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D014280:Triglycerides / Q000097:blood
chemical_list: D005227:Fatty Acids; D008055:Lipids; D008075:Lipoproteins, HDL; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D011355:Prodrugs; D011684:Purine Nucleosides; D014280:Triglycerides; C076195:Agr 540; C065348:N(6)-(amido-3-propyl)adenosine; D002784:Cholesterol; D000241:Adenosine